Medtronic plcMDT commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This happened following the U.S. FDA approval late last year.

Editor’s Note: A few weeks ago, a Type 1 diabetes patient authored a blog post about why she didn’t want to switch to Medtronic’s MiniMed 670G billed as the industry’s first hybrid closed-loop insulin ...

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...

On Wednesday, the FDA approved Medtronic’s hybrid closed-loop system, the world’s first “artificial pancreas.” The agency nod comes months ahead of the spring approval that the company had been ...

Medtronic touted new clinical data from its growing base of MiniMed 670G insulin-pump users, noting on Tuesday that people who used the pump's most advanced features kept their blood sugar levels ...

In a quick approval, the U.S. Food and Drug Administration on Wednesday gave a green light to the first medical device for type 1 diabetes that can automate varying doses of insulin 24 hours a day ...

The company's announcement notably does not use the term "artificial pancreas," although the technology is a considerably more significant advance from the 530G threshold suspend device of 2013. When ...

Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...